Phase II Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
Condition(s):Adenocarcinomas; Recurrent GynecologicalLast Updated:January 7, 2021Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Adenocarcinomas; Recurrent GynecologicalLast Updated:January 7, 2021Not yet recruiting
Condition(s):Dialysis Access Malfunction; End Stage Renal Failure on Dialysis; End Stage Renal Disease; Fistulas Arteriovenous; StenosisLast Updated:January 7, 2021Active, not recruiting
Condition(s):Mild Cognitive Impairment; FrailtyLast Updated:January 5, 2021Recruiting
Condition(s):Perinatal Problems; Mood Change; Stress-related ProblemLast Updated:December 28, 2020Recruiting
Condition(s):AdultsLast Updated:December 24, 2020Completed
Condition(s):HealthyLast Updated:January 5, 2021Not yet recruiting
Condition(s):HealthyLast Updated:January 6, 2021Not yet recruiting
Condition(s):Gastric Cancer; Esophageal Cancer; Esophagogastric Junction CancerLast Updated:December 19, 2020Recruiting
Condition(s):Dental CariesLast Updated:December 17, 2020Enrolling by invitation
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:December 11, 2020Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.